Recon: FDA approves higher dose of Regeneron’s Eylea; Gilead’s blood cancer drug trials placed on hold
ReconJason Scott
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy